What DBV Technologies does

DBV Technologies is a clinical-stage biopharmaceutical company developing epicutaneous immunotherapy (EPIT) treatments for food allergies using its proprietary VIASKIN patch platform. Founded in 2002 by pediatricians, the company is headquartered in Châtillon, France, with North American operations based in Warren, New Jersey. It is publicly traded on Euronext Paris (DBV) and Nasdaq (DBVT), with a market capitalization of approximately $1.17 billion as of April 2026 and 101-250 employees.

The company's core technology is a once-daily patch that delivers microgram quantities of allergen through intact skin. The patch creates a condensation chamber that allows antigen capture by Langerhans cells in the epidermis, which migrate to draining lymph nodes and activate allergen-specific regulatory T cells, attenuating the Th2 response without systemic allergen exposure. Its lead product, the VIASKIN Peanut Patch (DBV712), achieved positive Phase 3 VITESSE results in December 2025, with 46.6% of treated children aged 4-7 meeting responder criteria versus 14.8% on placebo (p<0.001). DBV is preparing two Biologics License Applications (BLAs) for FDA submission in 2026—one for ages 4-7 in the first half and a second for toddlers aged 1-3 in the second half. The pipeline also includes the VIASKIN Milk Patch (DBV135) for cow's milk allergy and a milk-induced eosinophilic esophagitis (EoE) indication.

The company is pre-revenue, with operations funded entirely through capital markets; it has raised approximately $276 million via 2025 PIPE and ATM programs and reported $229 million in cash as of March 31, 2026, with runway extending into Q2 2027. The commercial model is sales-led through physician prescribing by allergists and pediatricians, with distribution via specialty pharmacy and healthcare provider channels once approved. DBV has appointed a Chief Commercial Officer and is building U.S. commercial-readiness infrastructure in preparation for potential launches in 2027.

Name

DBV Technologies

Legal name

DBV Technologies

Website

https://dbv-technologies.com

Company type

Public

Founded year

2002

Operating status

Operating

Headcount range

51–100 employees

Short description

DBV Technologies is a France-based clinical-stage biopharmaceutical company developing once-daily VIASKIN epicutaneous immunotherapy patches for peanut and other food allergies in children, preparing BLA submissions to the FDA in 2026 following positive Phase 3 VITESSE results.

Ownership category

akta.pro rank

Product category

Food Allergy Immunotherapy

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Allergy Immunotherapy Biologics (allergen extracts, desensitization) (HLAAAEAI)

akta.pro secondary industries

Pediatric Allergy & Immunology (HLAKAAAB), Allergy & Immunology Clinics (HLAKAAAA)

Keywords

• Epicutaneous immunotherapy
• Food allergy treatment
• Biopharmaceutical products
• Allergy immunotherapy patches
• Clinical-stage biopharma

Headquarters

HQ city

Châtillon

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Pharmaceutical Product Sales: DBV Technologies is a clinical-stage biopharmaceutical company with no current product revenue. It plans to generate revenue through the sale of its VIASKIN patch products upon regulatory approval. The company is preparing for commercial launches in the United States for its peanut allergy patch in pediatric populations (4-7 years and 1-3 years), with BLA submissions planned for 2026. Revenue will come from product sales to healthcare providers, pharmacies, and healthcare systems, likely reimbursed through insurance and government payors.
2. Equity Financing / ATM Programs: The company has raised capital through At-The-Market (ATM) programs on Nasdaq (approximately $30 million sold in October 2025) and private placement financings ($194 million in June 2022, ~$276 million through 2025 PIPE and ATM). These are financing events rather than revenue operations, used to fund clinical development and pre-commercial activities.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels6 records

Core offering

DBV Technologies develops proprietary epicutaneous immunotherapy (EPIT) patches via the VIASKIN® platform for the treatment of food allergies. The lead product candidate, VIASKIN Peanut Patch (DBV712), delivers microgram amounts of peanut protein through intact skin to desensitize peanut-allergic children aged 1-7 years, with BLA submissions planned for 2026. The portfolio also includes VIASKIN Milk Patch (DBV135) for cow's milk allergy and an eosinophilic esophagitis indication. All products are investigational and have not yet received regulatory approval.

Product overview

DBV Technologies is a late-stage biopharmaceutical company developing a portfolio of treatments for food allergies using its proprietary VIASKIN epicutaneous immunotherapy (EPIT) platform. The core product portfolio includes the VIASKIN Peanut Patch (DBV712) for peanut allergy in children aged 1-7 years, the VIASKIN Milk Patch (DBV135) for cow's milk allergy, and the VIASKIN Milk Patch for EoE (Eosinophilic Esophagitis). All products are investigational medical devices-drug combinations that have not been approved by any regulatory authority. The company is preparing for BLA submissions with the FDA targeting first half of 2026 for the peanut patch in children 4-7 years.

Differentiator

Problem solved

Functional benefit

Brands

• VIASKIN: Proprietary epicutaneous immunotherapy (EPIT) patch technology platform for treating food allergies and other immunologic conditions. Includes VIASKIN Peanut Patch (DBV712) and VIASKIN Milk Patch (DBV135).
• VITESSE
• EPITOPE
• THRIVE
• COMFORT Toddlers

Products and services

• VIASKIN Peanut Patch (DBV712) Epicutaneous immunotherapy (EPIT) patch delivering microgram amounts of peanut protein through intact skin once daily for desensitization of peanut-allergic children aged 1-7 years. Indicated for pediatric patients with confirmed peanut allergy, including those with atopic comorbidities such as asthma, additional food allergies, and atopic dermatitis. Investigational drug-device combination product; not yet approved by any regulatory authority.
• VIASKIN Milk Patch (DBV135) Epicutaneous immunotherapy patch delivering cow's milk protein antigens through intact skin for desensitization of pediatric and adolescent patients with IgE-mediated cow's milk protein allergy. Investigational product; not yet approved by any regulatory authority.
• VIASKIN Milk Patch for Eosinophilic Esophagitis (EoE) Investigation of the VIASKIN Milk patch for treatment of cow's milk-induced Eosinophilic Esophagitis (EoE) in children and adolescents aged 4-17 years. Conducted under a sponsored research collaboration with CHOP. Investigational indication; not yet approved.

Quantifiable outcome

• 46.6% treatment responder rate vs 14.8% placebo (p<0.001) at 12 months in peanut-allergic children aged 4-7 years in Phase 3 VITESSE trial
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core and notable.

• Citibank, N.A.coreOthersCitibank, N.A. serves as the depositary bank for DBV Technologies' American Depositary Shares (ADSs) traded on Nasdaq (DBVT). Each ADS represents five ordinary shares. The depositary's offices are at 388 Greenwich Street, New York, NY 10013, with the custodian being Citibank Europe Plc Dublin.
• Children's Hospital of Philadelphia (CHOP)notableStrategic or Co-development PartnerCHOP sponsored and conducted the SMILEE Phase 2a clinical trial evaluating the efficacy and safety of the VIASKIN Milk patch for eosinophilic esophagitis (EoE) induced by cow's milk in children aged 4-17 years. The trial enrolled 20 subjects in the blinded portion and 19 in the open-label extension.
• National Institute of Allergy and Infectious Diseases (NIAID) / NIHnotableStrategic or Co-development PartnerThe NIAID, an institute of the U.S. National Institutes of Health, sponsored and funded the CoFAR6 clinical trial evaluating the VIASKIN Peanut patch in children and adults aged 4-25 years. This was a multicenter, randomized, double-blind, placebo-controlled trial.
• Assistance Publique-Hôpitaux de Paris (AP-HP)notableStrategic or Co-development PartnerAP-HP sponsored the ARACHILD clinical trial, a multicenter, double-blind, placebo-controlled 18-month study evaluating the efficacy and safety of the VIASKIN Peanut patch in 54 children aged 5-17 years. AP-HP also collaborated on a pilot EPIT study for cow's milk allergy.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Aimmune Therapeutics: Developed Palforzia, the first FDA-approved oral immunotherapy for peanut allergy in children, making it the closest direct peer to DBV in peanut allergy desensitization, although Aimmune pursued an oral rather than epicutaneous route.

Broad incumbents

• ALK-Abelló: Global leader in allergy immunotherapy (subcutaneous and sublingual) for respiratory and venom allergies, with a broad commercial infrastructure and pipeline that overlaps DBV's allergy desensitization focus; also an early DBV investor.
• Stallergenes Greer: Specialty biopharmaceutical company focused on allergy immunotherapy diagnosis and treatment, now part of the same food allergy treatment landscape and a relevant comparator for DBV's commercial strategy in allergen-specific desensitization.
• Sanofi (Dupixent franchise): Markets dupilumab (Dupixent) for conditions including eosinophilic esophagitis and atopic dermatitis — directly adjacent to DBV's EoE and atopic comorbidity populations — and represents a well-capitalized incumbent competitor in the allergy/inflammation specialty channel.
• Regeneron Pharmaceuticals: Co-developer of dupilumab (with Sanofi), with deep immunology pipeline and significant commercial reach in pediatric allergy/asthma specialty markets where DBV's VIASKIN patch would need to compete for prescriber mindshare and formulary access.

Emerging players

• Alladapt Immunotherapeutics: Clinical-stage company developing an oral immunotherapy for multi-food allergy, with a similar indication footprint to DBV but a different delivery modality; represents a near-term competitive threat in the broader food allergy desensitization market.
• Intrommune Therapeutics: Developing an oral mucosal immunotherapy (OMIT) platform for food allergy, providing an alternative non-injectable route to desensitization that overlaps with DBV's mission and could compete on patient experience.
• Prota Therapeutics: Australian clinical-stage company developing an oral immunotherapy for peanut allergy in pediatric patients, providing another peanut-specific competitor that targets the same regulatory and reimbursement pathway as DBV's peanut patch.

Others

• Nestlé Health Science: Acquired Aimmune Therapeutics and holds commercial rights to Palforzia; serves as a strategic comparator for what scaled food allergy commercialization looks like and a potential acquirer or strategic partner of last resort for DBV.
• Viatris: Large specialty/generics pharmaceutical company with established allergy, respiratory, and immunology commercial infrastructure that could serve as a strategic partner or distribution backbone for VIASKIN patch commercialization in the U.S.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/dbvtechnologies
• Facebookfacebook.com/dbv-technologies-222890957906209
• LinkedInlinkedin.com/company/dbv-technologies

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries2 records

Funding overview

Funding rounds12 records

Investors23 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DBV Technologies